Justine M Kahn1, Kara M Kelly2, Qinglin Pei3, Rizvan Bush4, Debra L Friedman5, Frank G Keller6, Smita Bhatia7, Tara O Henderson8, Cindy L Schwartz9, Sharon M Castellino6. 1. Columbia University Irving Medical Center, New York, NY. 2. Roswell Park Comprehensive Cancer Center, Buffalo, NY. 3. Children's Oncology Group Statistics and Data Center, University of Florida, Gainesville, FL. 4. Children's Oncology Group Statistics and Data Center, Monrovia, CA. 5. Vanderbilt University School of Medicine, Nashville, TN. 6. Emory University School of Medicine, Atlanta, GA. 7. University of Alabama at Birmingham, Birmingham, AL. 8. University of Chicago Comer Children's Hospital, Chicago, IL. 9. Medical College of Wisconsin, Milwaukee, WI.
Abstract
PURPOSE: Population-based studies of children and adolescents with Hodgkin lymphoma (HL) report a survival disadvantage in nonwhite-non-Hispanic black (NHB) and Hispanic-patients. Whether disparities persist after adjustment for clinical and treatment-related variables is unknown. We examined survival by race/ethnicity in children receiving risk-based, response-adapted, combined-modality therapy for HL in contemporary Children's Oncology Group trials. PATIENTS AND METHODS: This pooled analysis used individual-level data from 1,605 patients (younger than age 1 to 21 years) enrolled in phase III trials for low-risk (AHOD0431), intermediate-risk (AHOD0031), and high-risk (AHOD0831) HL from 2002 to 2012. Event-free survival (EFS) and overall survival (OS) were compared between non-Hispanic white (NHW) and nonwhite patients. Cox proportional hazards for survival were estimated for both de novo and relapsed HL, adjusting for demographics, disease characteristics, and therapy. RESULTS: At median follow up of 6.9 years, cumulative incidence of relapse was 17%. Unadjusted 5-year EFS and OS were 83% (SE, 1.2%) and 97% (SE, < 1%), respectively. Neither differed by race/ethnicity. In multivariable analyses for OS, nonwhite patients had a 1.88× higher hazard of death (95% CI, 1.1 to 3.3). Five-year postrelapse survival probabilities by race were as follows: NHW, 90%; NHB, 66%; and Hispanic, 80% (P < .01). Compared with NHW, Hispanic and NHB children had 2.7-fold (95% CI, 1.2 to 6.2) and 3.5-fold (95% CI, 1.5 to 8.2) higher hazard of postrelapse mortality, respectively. CONCLUSION: In patients who were treated for de novo HL in contemporary Children's Oncology Group trials, EFS did not differ by race/ethnicity; however, adjusted OS was significantly worse in nonwhite patients, a finding driven by increased postrelapse mortality in this population. Additional studies examining treatment and survival disparities after relapse are warranted.
PURPOSE: Population-based studies of children and adolescents with Hodgkin lymphoma (HL) report a survival disadvantage in nonwhite-non-Hispanic black (NHB) and Hispanic-patients. Whether disparities persist after adjustment for clinical and treatment-related variables is unknown. We examined survival by race/ethnicity in children receiving risk-based, response-adapted, combined-modality therapy for HL in contemporary Children's Oncology Group trials. PATIENTS AND METHODS: This pooled analysis used individual-level data from 1,605 patients (younger than age 1 to 21 years) enrolled in phase III trials for low-risk (AHOD0431), intermediate-risk (AHOD0031), and high-risk (AHOD0831) HL from 2002 to 2012. Event-free survival (EFS) and overall survival (OS) were compared between non-Hispanic white (NHW) and nonwhite patients. Cox proportional hazards for survival were estimated for both de novo and relapsed HL, adjusting for demographics, disease characteristics, and therapy. RESULTS: At median follow up of 6.9 years, cumulative incidence of relapse was 17%. Unadjusted 5-year EFS and OS were 83% (SE, 1.2%) and 97% (SE, < 1%), respectively. Neither differed by race/ethnicity. In multivariable analyses for OS, nonwhite patients had a 1.88× higher hazard of death (95% CI, 1.1 to 3.3). Five-year postrelapse survival probabilities by race were as follows: NHW, 90%; NHB, 66%; and Hispanic, 80% (P < .01). Compared with NHW, Hispanic and NHB children had 2.7-fold (95% CI, 1.2 to 6.2) and 3.5-fold (95% CI, 1.5 to 8.2) higher hazard of postrelapse mortality, respectively. CONCLUSION: In patients who were treated for de novo HL in contemporary Children's Oncology Group trials, EFS did not differ by race/ethnicity; however, adjusted OS was significantly worse in nonwhite patients, a finding driven by increased postrelapse mortality in this population. Additional studies examining treatment and survival disparities after relapse are warranted.
Authors: Frank G Keller; Sharon M Castellino; Lu Chen; Qinglin Pei; Stephan D Voss; Kathleen M McCarten; Stacy L Senn; Allen B Buxton; Rizvan Bush; Louis S Constine; Cindy L Schwartz Journal: Cancer Date: 2018-05-08 Impact factor: 6.860
Authors: Ajay K Gopal; Robert Chen; Scott E Smith; Stephen M Ansell; Joseph D Rosenblatt; Kerry J Savage; Joseph M Connors; Andreas Engert; Emily K Larsen; Xuedong Chi; Eric L Sievers; Anas Younes Journal: Blood Date: 2014-12-22 Impact factor: 22.113
Authors: Regina M Myers; Brian T Hill; Bronwen E Shaw; Soyoung Kim; Heather R Millard; Minoo Battiwalla; Navneet S Majhail; David Buchbinder; Hillard M Lazarus; Bipin N Savani; Mary E D Flowers; Anita D'Souza; Matthew J Ehrhardt; Amelia Langston; Jean A Yared; Robert J Hayashi; Andrew Daly; Richard F Olsson; Yoshihiro Inamoto; Adriana K Malone; Zachariah DeFilipp; Steven P Margossian; Anne B Warwick; Samantha Jaglowski; Amer Beitinjaneh; Henry Fung; Kimberly A Kasow; David I Marks; Jana Reynolds; Keith Stockerl-Goldstein; Baldeep Wirk; William A Wood; Mehdi Hamadani; Prakash Satwani Journal: Cancer Date: 2017-11-10 Impact factor: 6.860
Authors: Justine M Kahn; Peter D Cole; Traci M Blonquist; Kristen Stevenson; Zhezhen Jin; Sergio Barrera; Randy Davila; Emily Roberts; Donna S Neuberg; Uma H Athale; Luis A Clavell; Caroline Laverdiere; Jean-Marie Leclerc; Bruno Michon; Marshall A Schorin; Jennifer J G Welch; Stephen E Sallan; Lewis B Silverman; Kara M Kelly Journal: Pediatr Blood Cancer Date: 2017-11-01 Impact factor: 3.167
Authors: Nancy Krieger; Jarvis T Chen; Pamela D Waterman; David H Rehkopf; S V Subramanian Journal: Am J Public Health Date: 2005-02 Impact factor: 9.308
Authors: Smita Bhatia; Harland N Sather; Nyla A Heerema; Michael E Trigg; Paul S Gaynon; Leslie L Robison Journal: Blood Date: 2002-09-15 Impact factor: 22.113
Authors: Sally L Glaser; Margaret L Gulley; Christina A Clarke; Theresa H Keegan; Ellen T Chang; Sarah J Shema; Fiona E Craig; Joseph A Digiuseppe; Ronald F Dorfman; Risa B Mann; Hoda Anton-Culver; Richard F Ambinder Journal: Int J Cancer Date: 2008-10-01 Impact factor: 7.396
Authors: Mindy C DeRouen; Helen M Parsons; Erin E Kent; Brad H Pollock; Theresa H M Keegan Journal: Cancer Causes Control Date: 2017-06-28 Impact factor: 2.532
Authors: Justine M Kahn; Qinglin Pei; Debra L Friedman; Joel Kaplan; Frank G Keller; David Hodgson; Yue Wu; Burton E Appel; Smita Bhatia; Tara O Henderson; Cindy L Schwartz; Kara M Kelly; Sharon M Castellino Journal: Lancet Haematol Date: 2022-01 Impact factor: 18.959
Authors: Rahul R Parikh; Kara M Kelly; David C Hodgson; Bradford S Hoppe; Kathleen M McCarten; Katie Karolczuk; Qinglin Pei; Yue Wu; Steve Y Cho; Cindy Schwartz; Peter D Cole; Kenneth Roberts Journal: Int J Radiat Oncol Biol Phys Date: 2021-11-09 Impact factor: 7.038
Authors: Justine M Kahn; Frances B Maguire; Qian Li; Renata Abrahão; Jamie E Flerlage; Elysia Alvarez; Theresa H M Keegan Journal: Cancer Date: 2021-09-08 Impact factor: 6.860
Authors: Amy M Berkman; Clark R Andersen; Vidya Puthenpura; J A Livingston; Sairah Ahmed; Branko Cuglievan; Michelle A T Hildebrandt; Michael E Roth Journal: Cancer Epidemiol Date: 2021-09-28 Impact factor: 2.984
Authors: Eric J Chow; Lena E Winestone; Philip J Lupo; Lisa R Diller; Tara O Henderson; Nina S Kadan-Lottick; Jennifer M Levine; Kirsten K Ness; Smita Bhatia; Saro H Armenian Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-09-02 Impact factor: 4.090
Authors: Justine M Kahn; Xiuling Zhang; Amy R Kahn; Sharon M Castellino; Alfred I Neugut; Maria J Schymura; Francis P Boscoe; Theresa H M Keegan Journal: J Adolesc Young Adult Oncol Date: 2021-10-08 Impact factor: 1.757
Authors: Jennifer E Agrusa; Brooks P Scull; Harshal A Abhyankar; Howard Lin; Nmazuo W Ozuah; Rikhia Chakraborty; Olive S Eckstein; Nitya Gulati; Elmoataz Abdel Fattah; Nader K El-Mallawany; Rayne H Rouce; ZoAnn E Dreyer; Julienne Brackett; Judith F Margolin; Joseph Lubega; Terzah M Horton; Catherine M Bollard; M Monica Gramatges; Kala Y Kamdar; Kenneth L McClain; Tsz-Kwong Man; Carl E Allen Journal: Cancers (Basel) Date: 2020-12-02 Impact factor: 6.639
Authors: Jae Min Lee; Jung Yoon Choi; Kyung Taek Hong; Hyoung Jin Kang; Hee Young Shin; Hee Jo Baek; Hoon Kook; Seongkoo Kim; Jae Wook Lee; Nack Gyun Chung; Bin Cho; Seok Goo Cho; Kyung Mi Park; Eu Jeen Yang; Young Tak Lim; Jin Kyung Suh; Sung Han Kang; Hyery Kim; Kyung Nam Koh; Ho Joon Im; Jong Jin Seo; Hee Won Cho; Hee Young Ju; Ji Won Lee; Keon Hee Yoo; Ki Woong Sung; Hong Hoe Koo; Kyung Duk Park; Jeong Ok Hah; Min Kyoung Kim; Jung Woo Han; Seung Min Hahn; Chuhl Joo Lyu; Ye Jee Shim; Heung Sik Kim; Young Rok Do; Jae Won Yoo; Yeon Jung Lim; In Sang Jeon; Hee Won Chueh; Sung Yong Oh; Hyoung Soo Choi; Jun Eun Park; Jun Ah Lee; Hyeon Jin Park; Byung Kiu Park; Soon Ki Kim; Jae Young Lim; Eun Sil Park; Sang Kyu Park; Eun Jin Choi; Young Bae Choi; Jong Hyung Yoon Journal: J Korean Med Sci Date: 2020-11-30 Impact factor: 2.153